Uncategorized

Zymergen Shares Indicated $36

byMichael Horton

April 22, 2021

0 minute read

Jefferies Initiates Coverage On Relay Therapeutics with Underperform Rating, Announces Price Target of $13

By Benzinga Newsdesk

Today, 7:18 AM

Jefferies analyst Akash Tewari initiates coverage on Relay Therapeutics (NASDAQ:RLAY) with a Underperform rating and announces Price Target of $13.

RLAY

‘Stick To Space Elon,’ Billboards Criticizing Musk Over Bitcoin Stance To Appear Across US

By Shivdeep Dhaliwal

Today, 7:18 AM

National Football League player Russell Okung is putting up billboards aimed at Tesla Inc (NASDAQ: TSLA) and SpaceX CEO Elon Musk due to his recent utterances on Bitcoin (BTC), Decry

TSLA

Citigroup Downgrades Blueprint Medicines to Sell, Lowers Price Target to $41

By Benzinga Newsdesk

Today, 7:18 AM

Citigroup analyst David Lebowitz downgrades Blueprint Medicines (NASDAQ:BPMC) from Neutral to Sell and lowers the price target from $68 to $41.

BPMC

News
Tech

Cerebral Under Fire For Sharing Sensitive Health Data Of 3.1M US Patients With Google, Meta, TikTok

By Ananya Gairola

Today, 7:18 AM

Health startup Cerebral is facing intense scrutiny and backlash after it inadvertently shared private data with tech giants…

GOOG

Zymergen Shares Indicated $36

Related Posts

Jefferies Initiates Coverage On Relay Therapeutics with Underperform Rating, Announces Price Target of $13

‘Stick To Space Elon,’ Billboards Criticizing Musk Over Bitcoin Stance To Appear Across US

Citigroup Downgrades Blueprint Medicines to Sell, Lowers Price Target to $41

Cerebral Under Fire For Sharing Sensitive Health Data Of 3.1M US Patients With Google, Meta, TikTok